Japan Approves First Humira Biosimilar
Mylan Will Market Fujifilm Kyowa Kirin’s Adalimumab Rival In Japan
Executive Summary
Japan has approved its first biosimilar rival to Humira. Mylan is set to market the Fujifilm Kyowa Kirin Biologics adalimumab biosimilar, having already launched the product as Hulio in Europe.
You may also be interested in...
Mochida And Ayumi Launch Unique Humira Biosimilar Formulation In Japan
A new formulation of biosimilar Humira is now available in Japan, alongside three other presentations that join biosimilar products launched by partners Viatris and Fujifilm Kyowa Kirin Biologics at the start of this year.
Viatris And FKB Introduce First Japanese Adalimumab Biosimilar
Viatris and Fujifilm Kyowa Kirin Biologics have introduced Japan’s first biosimilar rival to Humira.
Sun Sees US Sales Pick Up
Sun enjoyed a sequential improvement in its US sales in Q2, with finished-dosage turnover in the market up by almost a fifth over the financial first quarter. Meanwhile, the Indian company is hoping to build on early momentum for its psoriasis therapy Ilumya in Japan, leveraging the dermatology expertise of acquired local company Pola.